Adaptive Biotechnologies Corp [ADPT] stock is trading at $18.07, down -1.04%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ADPT shares have gain 12.17% over the last week, with a monthly amount glided 17.19%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Guggenheim started tracking the stock with Buy rating on September 30, 2025, and set its price target to $20. On June 18, 2025, Craig Hallum initiated with a Buy rating and assigned a price target of $15 on the stock. Goldman upgraded its rating to a Buy but stick to its price target of $9 on March 21, 2025. Scotiabank started tracking with a Sector Outperform rating for this stock on January 05, 2023, and assigned it a price target of $15. In a note dated December 21, 2022, Piper Sandler upgraded an Overweight rating on this stock and boosted its target price from $7.50 to $14.
Adaptive Biotechnologies Corp [ADPT] stock has fluctuated between $5.97 and $20.76 over the past year. Currently, Wall Street analysts expect the stock to reach $20.33 within the next 12 months. Adaptive Biotechnologies Corp [NASDAQ: ADPT] shares were valued at $18.07 at the most recent close of the market. An investor can expect a potential return of 12.51% based on the average ADPT price forecast.
Analyzing the ADPT fundamentals
Adaptive Biotechnologies Corp [NASDAQ:ADPT] reported sales of 252.75M for the trailing twelve months, which represents a growth of 102.38%. Gross Profit Margin for this corporation currently stands at 0.72% with Operating Profit Margin at -0.31%, Pretax Profit Margin comes in at -0.31%, and Net Profit Margin reading is -0.31%. To continue investigating profitability, this company’s Return on Assets is posted at -0.16, Equity is -0.41 and Total Capital is -0.19. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Adaptive Biotechnologies Corp’s Current Ratio is 3.38. As well, the Quick Ratio is 3.26, while the Cash Ratio is 0.66. Considering the valuation of this stock, the price to sales ratio is 10.91, the price to book ratio is 13.49.
Transactions by insiders
Recent insider trading involved FRANCIS LO, Officer, that happened on Jan 12 ’26 when 64293.0 shares were purchased. Officer, KYLE PISKEL completed a deal on Jan 12 ’26 to buy 11081.0 shares. Meanwhile, Chief Scientific Officer ROBINS HARLAN S sold 10000.0 shares on Jan 06 ’26.
